Company intelligence / Profile preview

Biliang

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Biliang Biotech is a biopharmaceutical company based in Suzhou, China, specializing in the development of innovative RNA interference (RNAi) therapeutics. The company leverages a proprietary lipid nanoparticle (LNP) delivery platform to develop small interfering RNA (siRNA) drugs targeting metabolic and cardiovascular diseases. Their current pipeline includes programs focused on regulating lipid metabolism through targets such as ANGPTL3 and PCSK9, as well as anticoagulation therapies. Biliang Biotech aims to overcome the delivery challenges of RNA drugs to provide long-acting, highly effective treatments for chronic conditions.

Therapeutic areas: CardiovascularMetabolic Disorders
Modalities: Small interfering RNALipid nanoparticle delivery therapyRNA therapy
Industry: Biotech

Beyond the preview

Go deeper on Biliang.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biliang.

Explore the full profile